Replies to post #165812 on Biotech Values

[DewDiligence]

PTLA’s PRT-4445 appears to work; however, as noted in #msg-91053501, I don’t think PTLA’s plan for phase-3 will pass muster with the FDA.

[DewDiligence]

PTLA’s BLA submission for PRT4445 in 2015 will include data on the reversibility of all FXa inhibitors* as well as Lovenox and other LMWH’s. (Source: Today’s MS webcast.) Good luck with that, LOL; my opinion in #msg-91053501 remains unchanged.

*Xarelto, Elliquis, Edoxaban, Betrixaban.